GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
74.44
-1.24 (-1.64%)
At close: 4:00PM EDT

74.43 -0.01 (-0.02%)
After hours: 5:24PM EDT

Stock chart is not supported by your current browser
Previous Close75.68
Open75.42
Bid74.14 x 100
Ask74.92 x 100
Day's Range73.83 - 75.92
52 Week Range63.76 - 89.54
Volume3,460,265
Avg. Volume8,034,885
Market Cap97.059B
Beta1.35
PE Ratio (TTM)21.21
EPS (TTM)3.51
Earnings DateMay 1, 2018
Forward Dividend & Yield2.28 (3.03%)
Ex-Dividend Date2018-03-15
1y Target Est88.95
Trade prices are not sourced from all markets
  • Top Research Reports for IBM, McDonald's & Gilead
    Zacks8 hours ago

    Top Research Reports for IBM, McDonald's & Gilead

    Top Research Reports for IBM, McDonald's & Gilead

  • MarketWatch10 hours ago

    Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug

    Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...

  • Analysts’ Recommendations for Exelixis in April 2018
    Market Realist15 hours ago

    Analysts’ Recommendations for Exelixis in April 2018

    In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.

  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realist16 hours ago

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • PR Newswireyesterday

    Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

    TOKYO, April 18, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas" ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, "Kite"), today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realistyesterday

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...

  • What Analysts Recommend for Gilead Sciences in April 2018
    Market Realistyesterday

    What Analysts Recommend for Gilead Sciences in April 2018

    In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.

  • Investopediayesterday

    Why Big Biotech Stocks May Get An Earnings Boost

    Big Bounce: Big biotech stocks may surge on better-than-expected quarterly results

  • ETF Trendsyesterday

    Big Biotech ETF Can Bounce Back

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...

  • Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
    Zacks2 days ago

    Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

    The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

  • AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane
    Market Realist2 days ago

    AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

    In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.

  • Business Wire2 days ago

    Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018

    Gilead Sciences, Inc. announced today that its first quarter 2018 financial results will be released on Tuesday, May 1, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2018 and provide a general business update.

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist3 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • GlobeNewswire3 days ago

    New Research Coverage Highlights DexCom, Equinix, Fitbit, Gilead Sciences, Humana, and Microsoft — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Gilead (GILD) Presents Encouraging Data on NASH Therapies
    Zacks4 days ago

    Gilead (GILD) Presents Encouraging Data on NASH Therapies

    Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.

  • 3 Growth Stocks for Successful Investors
    Motley Fool4 days ago

    3 Growth Stocks for Successful Investors

    Investing success can sometimes be achieved by looking beyond the obvious choices. Check out the growth potential of Shopify, Atara Bio, and Criteo.

  • Johnson & Johnson’s Revenue Estimates for 1Q18
    Market Realist4 days ago

    Johnson & Johnson’s Revenue Estimates for 1Q18

    As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool6 days ago

    3 Top Healthcare Stocks to Buy in April

    April could be the perfect time to pick up shares in these top healthcare stocks.

  • Business Wire7 days ago

    Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018

    Gilead Sciences, Inc. today presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis , combining the apoptosis signal-regulating kinase 1 inhibitor selonsertib with either the Acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal Farnesoid X receptor agonist GS-9674.

  • The Wall Street Journal7 days ago

    [$$] How Big Biotech Can Win Back Investors

    Big biotech stocks are trading at their lowest valuations in years, but don’t underestimate their ability to turn things around quickly.

  • Motley Fool7 days ago

    Why One Drug Flop Tanked Incyte's Stock

    Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.

  • Silicon Valley’s 10 highest-paid CEOs of 2018 may not be who you'd expect
    American City Business Journals8 days ago

    Silicon Valley’s 10 highest-paid CEOs of 2018 may not be who you'd expect

    You’d think Silicon Valley’s most visible CEOs — Mark Zuckerberg, Elon Musk, Sundar Pichai and Tim Cook — would crack the top 100. In fact, just one does. And the highest-paid CEO in the U.S. in 2017, the data shows, is a hard-charging dealmaker who heads up a San Jose-based tech company.

  • Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
    CNBC8 days ago

    Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'

    Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.

  • This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous
    Motley Fool8 days ago

    This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous

    There's a new kid on the CAR-T block.

  • Barrons.com9 days ago

    [$$] An S&P 500-Topping Advisor Dumps Its GE Stake

    Mark Keller, chief executive and chief investment officer of Confluence Investment Management, focuses on conglomerates, so it’s not surprising that the advisor had held a large position in General Electric. What’s surprising is that Confluence, which is based in St. Louis, sold in the first quarter all 2.8 million GE (GE) shares that it had held at the end of 2017, according to regulatory filings. Elsewhere, Keller and Confluence, which managed $5.4 billion in U.S.-traded securities at the end of the first quarter, was in a mood for buying well-known names in the period.